肝功能生化检查异常的评估
本文综述了肝功能生化检查(ALT、AST、ALP、胆红素、凝血酶原时间、白蛋白)在筛查和识别急慢性肝病中的应用,阐述了肝细胞损伤与胆汁淤积的指标模式,并系统介绍了异常结果的评估流程,包括病史采集、影像学、弹性成像及无创肝纤维化评分,最后讨论了肝活检的有限作用。
要点
- ALT/AST升高反映肝细胞损伤,INR延长伴胆红素升高需紧急评估。
- ALP升高反映胆汁淤积,胆红素可随肝细胞或胆汁淤积性损伤升高。
- 评估包括病史(代谢因素、酒精、药物、草药/膳食补充剂)、体格检查及腹部影像。
核心结论
- 肝功能生化检查异常需结合病史、影像学及无创纤维化评估确定病因、急性程度及并发症。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- ALT和AST升高反映肝细胞损伤,INR延长和胆红素升高提示需更紧急评估。
- ALP升高反映胆汁淤积和胆汁流受损,胆红素在肝细胞性或胆汁淤积性损伤中均可升高。
- 白蛋白、凝血酶原时间和胆红素是肝功能指标。
- 腹部影像提供肝脏形态、脂肪变、胆管扩张和门脉高压信息,弹性成像提供纤维化和脂肪变信息。
- 无创肝纤维化评估包括FIB-4和APRI,许多专有检测纳入肝功能生化指标。
关键数值与推荐
- 肝功能检查可用于评估预后,尤其在肝硬化、酒精相关肝病和代谢功能障碍相关脂肪性肝病患者中。
- 危重症患者肝酶升高常反映严重肝细胞损伤,化疗和免疫检查点抑制剂治疗者肝酶升高常提示肝毒性。
- 若无法确定肝功能异常原因,应排查肝外原因。
临床怎么用
- 对肝功能异常者,先详细采集代谢危险因素、酒精、药物及草药/膳食补充剂史并体检。
- 结合腹部影像和弹性成像评估肝形态、脂肪变、纤维化及门脉高压。
- 使用FIB-4或APRI等无创指标评估肝纤维化,肝活检作用已有限。
局限性
- 摘要未报告综述的检索范围及纳入文献标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liver biochemical and function tests-alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin, prothrombin time, and albumin-are used to screen and identify people with acute and chronic liver disease. Elevations in alanine aminotransferase and aspartate aminotransferase reflect hepatocellular injury, with more urgent evaluation required when the international normalized ratio of prothrombin is prolonged and the bilirubin level elevated. An elevation in alkaline phosphatase reflects a cholestatic process and impaired bile flow. Bilirubin may be elevated with either hepatocellular or cholestatic injury. Albumin, prothrombin time, and bilirubin are tests of hepatic function. Evaluation of abnormal liver tests includes history taking with attention to metabolic risk factors, alcohol, medications, and herbal/dietary supplements, followed by an examination, to determine the etiology of liver injury, acuity of illness, and presence of complications. Abdominal imaging provides information regarding liver morphology, steatosis, biliary dilatation, and portal hypertension. Elastography provides information about fibrosis and steatosis. If no explanation for abnormal liver tests can be determined, extrahepatic causes should be investigated. Liver tests used in the estimation of hepatic fibrosis include the fibrosis-4 index and aspartate aminotransferase-to-platelet ratio index. Many proprietary tests of hepatic fibrosis incorporate liver biochemical tests. Liver tests may also be used in the assessment of prognosis, particularly in people with cirrhosis, alcohol-associated liver disease, and metabolic dysfunction-associated steatotic liver disease. Liver test elevations in critically ill patients often reflect severe hepatocellular injury, whereas liver test elevations often indicate hepatotoxicity in people receiving chemotherapy and immune checkpoint inhibitors. With the availability of many approaches to assessing the diagnosis and severity of liver disease, the role of liver biopsy has become more limited.
引用
- Kwo PY, Masuoka HC, Schaefer EA, et al. Evaluation of Abnormal Liver Biochemical Test Results. Gastroenterology. 2026. PMID: 41831501. doi:10.1053/j.gastro.2025.12.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。